



Investigational Product Expanded Access Policy

Medicure is committed to the development of safe and effective medications to fill unmet needs of patients.

Expanded Access, sometimes referred to as compassionate use, is a program by which patients may gain access to investigational products outside of participation in approved clinical trials.

It is Medicure's position that investigational products should primarily be evaluated through the execution of approved clinical trials designed to establish data on product safety and efficacy. The data from these trials may then support approval of the drug by regulatory agencies.

As a general policy, Medicure will not provide investigational product outside of a clinical trial until adequate data is obtained to establish the safety and efficacy of the drug. The company may re-evaluate this policy when sufficient data is available.

If you have any questions about our investigational products, please contact Medicure at: info@medicure.com

Information on the Study of Oral MC-1 for the Treatment of Patients with PNPO Deficiency can be obtained at:
<https://clinicaltrials.gov/study/NCT04706013>